Trial Profile
Dupilumab in Severe Chronic Hand Eczema With Inadequate Response or Intolerance to Alitretinoin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Eczema
- Focus Proof of concept; Therapeutic Use
- Acronyms DUPSHE
- 12 May 2023 Status changed to completed, as per results published in the British Journal of Dermatology.
- 12 May 2023 Results assessing the efficacy and safety of dupilumab in patients with severe chronic hand eczema, published in the British Journal of Dermatology.
- 18 Aug 2022 Planned End Date changed from 1 Dec 2022 to 1 Aug 2022.